Weight loss drugs are set to become a disproportionate share of Lilly's business.

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Eli Lilly is sounding a warning on proposed tariffs on pharmaceuticals, saying it would raise costs and threaten patient access. The drugmaker said last week that the costs for breakthrough medicines ...

Eli Lilly shares have soared in the triple digits over the past year. Investors are excited about the company’s prospects in the high-growth, weight-loss drug market. Lilly's recently approved ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Regardless of your investment style, adding a few pharmaceutical stocks to your portfolio is a great idea. These players offer you a certain amount of stability because, no matter what's happening in ...

Eli Lilly (NYSE: LLY) stock has soared 90% over the past year, a huge gain for a pharmaceutical company. These stocks generally are known for steady increases over time instead of big movements over a ...